Development of Anti-Idiotype Monoclonal Antibodies for the Treatment of Breast Cancer.
Annual rept. 1 Jul 95-30 Jun 96,
KENTUCKY UNIV RESEARCH FOUNDATION LEXINGTON
Pagination or Media Count:
For the development of HER2neu anti-idiotype antibodies, groups of female BALBc mice were immunized with 454011 monoclonal antibodies directed at HER2neu. Hybridomas were generated by fusing spleen cells from immunized mice with non-secretory mouse myeloma cells. One Ab2 producing hybrid of 454011 was obtained, cloned by limiting dilution but showed declining production of Ab2. The specificity binding study using purilied 741F8 Ab2 and a series of mouse monoclonal antibodies belonging to different subclasses and directed against different antigens showed that the binding of 741F8 Ab2 was to those monoclonal antibodies directed against HER2neu. A competitive binding assay using 741F8 Ab2, Ab1 and the human breast cancer cell line SK-BR-3 which express HER2neu on their cell surface, showed that as little as lOng of purified 741F8 Ab2 inhibited the binding of Ab1 to SK-BR-3 cells by 50. Rabbits and mice have been immunized with purified 741F8 Ab2 to generate an Ab3 response.
- Medicine and Medical Research